Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Corcept Therapeutics Incorporated - Common Stock
(NQ:
CORT
)
38.34
-2.49 (-6.10%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Corcept Therapeutics Incorporated - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Looking for growth without the hefty price tag? Consider NASDAQ:CORT.
↗
January 31, 2025
CORCEPT THERAPEUTICS INC could be undervalued. NASDAQ:CORT is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced.
Via
Chartmill
Exploring NASDAQ:CORT's high growth characteristics.
↗
January 15, 2025
Is CORCEPT THERAPEUTICS INC (NASDAQ:CORT) suited for high growth investing?
Via
Chartmill
Exploring the Growth Potential of NASDAQ:CORT as It Nears a Breakout.
↗
January 15, 2025
CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a strong growth stock, setting up for a breakout.
Via
Chartmill
NASDAQ:CORT is not too expensive for the growth it is showing.
↗
January 10, 2025
For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering.
Via
Chartmill
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
↗
January 09, 2025
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Government
Exploring high growth characteristics of CORCEPT THERAPEUTICS INC (NASDAQ:CORT).
↗
December 12, 2024
Exploring high growth characteristics of CORCEPT THERAPEUTICS INC (NASDAQ:CORT).
Via
Chartmill
NASDAQ:CORT, a strong growth stock, setting up for a breakout.
↗
December 12, 2024
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) qualifies as a high growth stock and is consolidating.
Via
Chartmill
In the world of growth stocks, NASDAQ:CORT shines as a value proposition.
↗
November 04, 2024
Looking for growth without the hefty price tag? Consider NASDAQ:CORT.
Via
Chartmill
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism
December 30, 2024
From
Corcept Therapeutics Incorporated
Via
Business Wire
Investors should take note of NASDAQ:CORT, a growth stock that remains attractively priced.
↗
December 20, 2024
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) stands out as a growth opportunity that won't break the bank.
Via
Chartmill
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism
December 16, 2024
From
Corcept Therapeutics Incorporated
Via
Business Wire
Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes
↗
December 13, 2024
Corcept Therapeutics reports positive Phase 4 CATALYST results, showing Korlym significantly improves hemoglobin A1c in hypercortisolism patients.
Via
Benzinga
Earnings Preview: Corcept Therapeutics
↗
October 29, 2024
Via
Benzinga
Key Takeaways From Corcept Therapeutics Analyst Ratings
↗
October 18, 2024
Via
Benzinga
Is NASDAQ:CORT suited for high growth investing?
↗
October 17, 2024
Should you consider CORCEPT THERAPEUTICS INC (NASDAQ:CORT) for high growth investing?
Via
Chartmill
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes
December 12, 2024
From
Corcept Therapeutics Incorporated
Via
Business Wire
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)
December 11, 2024
From
Corcept Therapeutics Incorporated
Via
Business Wire
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
↗
December 11, 2024
NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.
Via
Investor's Business Daily
For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering.
↗
November 28, 2024
NASDAQ:CORT is showing decent growth, but is still valued reasonably.
Via
Chartmill
NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
↗
October 14, 2024
Is CORCEPT THERAPEUTICS INC (NASDAQ:CORT) on the Verge of a Major Breakout as a Strong Growth Stock?
Via
Chartmill
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
↗
October 08, 2024
NASDAQ:CORT is not too expensive for the growth it is showing.
Via
Chartmill
Forecasting The Future: 6 Analyst Projections For Corcept Therapeutics
↗
September 18, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
October 30, 2024
Via
Benzinga
Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update
October 30, 2024
From
Corcept Therapeutics Incorporated
Via
Business Wire
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
October 23, 2024
From
Corcept Therapeutics Incorporated
Via
Business Wire
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast
↗
September 30, 2024
Truist Securities raises the price target for Corcept Therapeutics to $76, driven by robust Korlym sales and promising relacorilant trials. The analyst highlights significant growth potential in the...
Via
Benzinga
NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
↗
September 09, 2024
Exploring the Growth Potential of CORCEPT THERAPEUTICS INC (NASDAQ:CORT) as It Nears a Breakout.
Via
Chartmill
NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
↗
August 16, 2024
CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via
Chartmill
NASDAQ:CORT is not too expensive for the growth it is showing.
↗
September 17, 2024
Investors should take note ofCORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock that remains attractively priced.
Via
Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering.
↗
August 27, 2024
Don't overlook CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—a stock with solid growth prospects and a reasonable valuation.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
